Value
6.3/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 7.2 |
| Fwd P/E | 2.1 |
| PEG | 10.0 |
| Analyst target | 5.0 |
- ▸Forward P/E: 54.8x
- ▸PEG: 0.37
WGS · Why this verdict
Why GeneDx Holdings (WGS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
GeneDx's quality score of 3.9 falls fractionally below the 4.0 investment minimum, driven by zero return on equity, zero operating margin, and a Rule of 40 score of only 18 — indicating the business has not yet converted its strong revenue growth into operational profitability. Quality breakdown | Quality score rises above 4.0 within 12 months as the company's Rule of 40 score improves above 25 through a combination of revenue growth sustaining above 20% and operating margins moving toward breakeven. | →Stable |
| CounterThe company is FCF-positive despite GAAP losses, with FCF margin of 1% and FCF yield of 0.2%; the GAAP quality concerns may overstate actual cash burn, and the path to GAAP profitability could be shorter than the current scores suggest. | ||
In the most recent quarter, GeneDx missed earnings by -1,408% surprise, against an estimate of -$0.02 versus an actual result of -$0.28 — a massive shortfall that suggests the path to profitability is less certain than prior quarters indicated. Earnings | The company returns to earnings beats in at least 2 of the next 3 quarters, with miss magnitude staying less severe than -50% surprise in any single quarter. | →Stable |
| CounterPrior quarters showed large beats of 16.7%, 15.9%, and 371.7%, indicating the one catastrophic miss may be an anomaly; the business can deliver well above expectations in favorable operational periods. | ||
A 30% short interest combined with a put/call ratio of 3.32 represents exceptional bearish conviction from sophisticated investors — the short interest level is flagged as 'justified' in the risk model, suggesting it is not a contrarian squeeze opportunity but a genuine fundamental concern. Risk breakdown | Short interest falls below 20% within 90 trading days as bearish investors cover, or at least 2 consecutive earnings beats cause a reduction in bearish positioning. | →Stable |
| CounterHigh short interest in a genomic diagnostics company with growing revenue and analyst upside of 26% may reflect an overly pessimistic market view; short covering alone could drive a significant rally if the thesis begins to validate. | ||
Despite the operational challenges, analyst consensus projects 26% upside to $66.99 with a strong average analyst rating, suggesting that the research community sees the current dislocated price as an overreaction to near-term earnings noise. Sentiment breakdown | Price rises above $66, more than 7% above the current $61.32, within 12 months as operational fundamentals begin to align with analyst expectations. | →Stable |
| CounterAnalyst coverage of 9 firms is flagged as 'light,' and coverage on early-stage healthcare companies often lags operational reality; the consensus upside may reflect outdated models that have not fully incorporated recent results. | ||
GeneDx's quality score of 3.9 falls fractionally below the 4.0 investment minimum, driven by zero return on equity, zero operating margin, and a Rule of 40 score of only 18 — indicating the business has not yet converted its strong revenue growth into operational profitability.
→StableQuality breakdown
- Expectation
- Quality score rises above 4.0 within 12 months as the company's Rule of 40 score improves above 25 through a combination of revenue growth sustaining above 20% and operating margins moving toward breakeven.
CounterThe company is FCF-positive despite GAAP losses, with FCF margin of 1% and FCF yield of 0.2%; the GAAP quality concerns may overstate actual cash burn, and the path to GAAP profitability could be shorter than the current scores suggest.
In the most recent quarter, GeneDx missed earnings by -1,408% surprise, against an estimate of -$0.02 versus an actual result of -$0.28 — a massive shortfall that suggests the path to profitability is less certain than prior quarters indicated.
→StableEarnings
- Expectation
- The company returns to earnings beats in at least 2 of the next 3 quarters, with miss magnitude staying less severe than -50% surprise in any single quarter.
CounterPrior quarters showed large beats of 16.7%, 15.9%, and 371.7%, indicating the one catastrophic miss may be an anomaly; the business can deliver well above expectations in favorable operational periods.
A 30% short interest combined with a put/call ratio of 3.32 represents exceptional bearish conviction from sophisticated investors — the short interest level is flagged as 'justified' in the risk model, suggesting it is not a contrarian squeeze opportunity but a genuine fundamental concern.
→StableRisk breakdown
- Expectation
- Short interest falls below 20% within 90 trading days as bearish investors cover, or at least 2 consecutive earnings beats cause a reduction in bearish positioning.
CounterHigh short interest in a genomic diagnostics company with growing revenue and analyst upside of 26% may reflect an overly pessimistic market view; short covering alone could drive a significant rally if the thesis begins to validate.
Despite the operational challenges, analyst consensus projects 26% upside to $66.99 with a strong average analyst rating, suggesting that the research community sees the current dislocated price as an overreaction to near-term earnings noise.
→StableSentiment breakdown
- Expectation
- Price rises above $66, more than 7% above the current $61.32, within 12 months as operational fundamentals begin to align with analyst expectations.
CounterAnalyst coverage of 9 firms is flagged as 'light,' and coverage on early-stage healthcare companies often lags operational reality; the consensus upside may reflect outdated models that have not fully incorporated recent results.
TrendMatrix Research · core thesis
Engine thesis — one sentence
GeneDx is a genomic diagnostics company with 84% revenue growth score and strong analyst consensus, but quality below the investment minimum at 3.9 out of 10, a 30% short interest, and a massive single-quarter earnings miss of -1,408% make this a high-risk situation requiring fundamental stabilization before new entry.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 9.9 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.9 |
| FCF quality | 3.2 |
| Moat | 6.5 |
| Rule of 40 | 3.0 |
| Piotroski F | 6.7 |
- ▸FCF-positive despite GAAP loss (FCF margin 1%, FCF yield 0.2%)
- ▸Rule of 40: 18 (fail)
Growth
8.4/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 6.9 |
| EPS growth | 10.0 |
Momentum
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 6.0 |
| Volume | 2.2 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -9.1%/30d — confirmed downtrend
Sentiment
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.8 |
| Analyst rating | 8.0 |
| Price target | 7.3 |
- ▸Light analyst coverage (9.0) — signal dampened
Insider
7.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 9.0 |
| insider conviction | 6.9 |
| holder change | 5.0 |
- ▸Heavy insider buying — $92,691,390 (4.625% of mkt cap)
Peer rank
3.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.7 |
| quality rank | 1.0 |
| growth rank | 6.3 |
Technical
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.4 |
| support resistance | 2.5 |
| 52w position | 0.0 |
Risk (lower is worse)
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.0 |
| days to cover | 6.0 |
| volatility | 0.0 |
| put call | 8.6 |
| implied vol | 0.0 |
| beta | 3.6 |
| debt equity | 7.0 |
- ▸High short interest justified: 39%
- ▸High IV: 89%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:4.7>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:25d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:0.1<1.5@spot
- DEATH_CROSS:HARD_BLOCK
Warning (1)
- MOMENTUM:4.7<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
0.07
Upside
+1.1%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 59
EdgeCatalyst-Driven — Earnings in 25d with 3/4 beat streak
SuitabilitySpeculative — Drawdown -60% (>40% off 52w high)
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 8.4 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:0.1<1.5@spot.
The strongest dimensions are Growth at 8.4, Sentiment at 7.1, and Insider at 7.0; the weakest are Technical at 1.6, Peer rank at 3.0, and Risk (lower is worse) at 3.6. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 0.07 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Just Below Floor
Trip ifRule of 40 score remains below 15 for at least 2 consecutive reported periods, confirming no near-term profitability improvement.
- P2Severe Earnings Miss Recent
Trip ifEarnings miss magnitude exceeds -100% surprise in at least 2 of the next 4 quarters.
- P3High Short Interest And Put Call
Trip ifShort interest rises above 35% or put/call ratio rises above 5 within the next 90 trading days.
- P4Strong Analyst Consensus Upside
Trip ifAnalyst consensus price target falls below $55, more than 18% below the current $61.32, reflecting a broad downgrade cycle.